Document ID: FDA-2018-N-1242-0002
Agency: fda
Document Type: Notice
Title: Advisory Committee; Arthritis Advisory Committee; Renewal
Posted Date: 2020-05-21T04:00Z

[Federal Register Volume 85, Number 99 (Thursday, May 21, 2020)]
[Notices]
[Page 30966]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-10996]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2018-N-1242]

Advisory Committee; Arthritis Advisory Committee; Renewal

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; renewal of advisory committee.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the 
renewal of the Arthritis Advisory Committee by the Commissioner of Food 
and Drugs (the Commissioner). The Commissioner has determined that it 
is in the public interest to renew the Arthritis Advisory Committee for 
an additional 2 years beyond the charter expiration date. The new 
charter will be in effect until April 5, 2022.

DATES: Authority for the Arthritis Advisory Committee would have 
expired on April 5, 2020, unless the Commissioner had formally 
determined that renewal is in the public interest.

FOR FURTHER INFORMATION CONTACT: Yinghua Wang, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-
796-9001, AAC@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Under 41 CFR 102-3, FDA is announcing the 
renewal of the Arthritis Advisory Committee. The Committee is a 
discretionary Federal advisory committee established to provide advice 
to the Commissioner or designee in discharging responsibilities as they 
relate to helping to ensure safe and effective drugs for human use and, 
as required, any other product for which FDA has regulatory 
responsibility.
    The Committee reviews and evaluates data concerning the safety and 
effectiveness of marketed and investigational human drug products for 
use in the treatment of arthritis, rheumatism, and related diseases, 
and makes appropriate recommendations to the Commissioner of Food and 
Drugs.
    Under its Charter, the Committee shall consist of a core of 11 
voting members including the Chair. Members and the Chair are selected 
by the Commissioner or designee from among authorities knowledgeable in 
the fields of arthritis, rheumatology, orthopedics, epidemiology or 
statistics, analgesics, and related specialties. Members will be 
invited to serve for overlapping terms of up to 4 years. Almost all 
non-Federal members of this committee serve as Special Government 
Employees. The core of voting members may include one technically 
qualified member, selected by the Commissioner or designee, who is 
identified with consumer interests and is recommended by either a 
consortium of consumer-oriented organizations or other interested 
persons. In addition to the voting members, the Committee may include 
one non-voting representative member who is identified with industry 
interests. There may also be an alternate industry representative.
    Further information regarding the most recent charter and other 
information can be found at https://www.fda.gov/advisory-committees/human-drug-advisory-committees/arthritis-advisory-committee or by 
contacting the Designated Federal Officer (see FOR FURTHER INFORMATION 
CONTACT). In light of the fact that no change has been made to the 
Committee name or description of duties, no amendment will be made to 
21 CFR 14.100.
    This document is issued under the Federal Advisory Committee Act (5 
U.S.C. app.). For general information related to FDA advisory 
committees, please check https://www.fda.gov/advisory-committees.

    Dated: May 18, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-10996 Filed 5-20-20; 8:45 am]
 BILLING CODE 4164-01-P